momentum
iqvia deliv robust close compani strong outlook
affirm convict iqvia enterpris strategi reson amidst
quarterli gross organ growth forecast iqvia cro
see win strategi appear reson market highlight
quarterli contract book-to-bil ttm basi given
iqvia scale clinic develop sheer magnitud new busi award
quarter impress technolog analyt solut iqvia oce strategi
appear reson approach renew cycl biopharma sponsor
compani post organ growth quarter call around
organ growth expect growth inflect exit year new oce
award begin contribut meaning growth post-implement
quarter cer revenu growth translat cash ebitda growth
cash ep growth highlight leverag inher iqvia busi model
fold factor togeth believ iqvia well posit head
continu deliv growth object reiter overweight
rate rais price target
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid cash ep
risk around deploy relat major new
award could pressur margin expans csm
segment growth could weigh near-term result
downsid case repres
downsid cash ep
iqvia deliv robust close compani strong outlook affirm
convict iqvia enterpris strategi reson amidst healthi fund
growth forecast iqvia cro see win
strategi appear reson market highlight quarterli contract
book-to-bil ttm basi given iqvia scale clinic
develop sheer magnitud new busi award quarter impress
technolog analyt solut iqvia oce strategi appear reson
approach renew cycl biopharma sponsor compani post
organ growth quarter call around organ growth
expect growth inflect exit year new oce award begin contribut
meaning growth post-implement quarter cer revenu
growth translat cash ebitda growth cash ep growth highlight
leverag inher iqvia busi model fold factor togeth
believ iqvia well posit head continu deliv growth
object reiter overweight rate rais price target
rais price target given increas convict
underli growth trajectori pt repres cash ep
prior price target base prior adj ebitda estim
billion repres prior cash ep forecast iqvia
recent new busi win out-pac peer believ support view
growth across analyt solut segment
specif iqvia deliv quarterli contract book-to-bil ttm
believ improv visibl solut growth ta
segment iqvia continu build momentum compani oce strategi
drive inflect revenu growth exit
one highlight iqvia earn compani contract
quarterli book-to-bil almost ttm basi screen higher
compani peer group iqvia continu show progress strategi
develop gener cro ceo bousbib highlight million award
quarter believ first increment new busi award compani
part nextgen data capabl start contribut meaning
growth importantli compani nextgen data capabl help
win busi exist client iqvia gain traction new custom
addit compani encourag win achiev leverag nextgen
platform smaller biopharma custom client base iqvia histor
under-penetrated compani note larg pharma custom account
next gen book quarter offer introduc
interestingli patient recruit next gen trial take place
unit state compani note believ nextgen offer impact
roughli compani rfp volum nextgen volum compani
expand use fix price contract
look iqvia underli result estim organ growth
held strong around basi given new busi win billion
quarterli book-to-bil underli net revenu segment
roughli quarter impli underli organ growth segment
around vs headlin organ growth background
must includ reimburs pass-through expens part gross revenu
histor net
assumpt busi analysisr begin new y/i cancel net y/i net net y/i new net y/i recogn growth burn move average burn end backlog w/ growth end backlog growth net net growth y/i growth contribut organ growth organ barclay iqvia
adjust revenu billion grew y/i estim
billion well upper end rang manag
guidanc billion compani note beat driven split
organ growth pass revenu currenc neutral growth
estim fx headwind revenu growth organ growth
roughli segment perspect result compani two
import segment drove beat technolog analyt solut
 solut revenu million grew y/i constant currenc
compani strongest result year
total revenu increas includ headwind fx revenu came
forecast million stronger
forecast assum ad growth impli organ growth
quarter compani net book-to-bil book impli
net revenu around quarter impli around net organ growth
segment
technolog analyt solut revenu million grew y/i constant
currenc includ headwind fx came
forecast million constant currenc growth beat
model organ growth quarter impli roughli
benefit bousbib ad iqvia see earli success
orchestr clinic engag oce offer win contract
contract sale medic solut revenu million declin
constant currenc though start stabil follow double-digit declin
throughout overal growth declin includ headwind
fx organ growth forecast
primari driver overal revenu estim million
iqvia initi guidanc strong project growth see futur
opportun ahead compani new busi win matur revenu
contribut revenu expect rang billion y/i
embed guidanc fx headwind addit expect
tailwind ta iqvia
guid organ growth segment basi iqvia guid ex-fx
growth ta growth roughli flat csm
ebitda forecast rang billion
midpoint ep forecast rang repres
growth includ project adjust book tax rate cash tax
iqvia guidanc impli revenu rang billion
repres growth y/i ebitda project rang
million y/i ep repres growth y/i
ebitda million came expect million
ebitda margin came expect margin declin
y/i iqvia track achiev million expect cost synergi
end
iqvia ebitda margin
cog increas y/i core sg ex-comp y/i
remind merger im health quintil complet octob
iqvia annual mix benefit im attract margin profil
gross margin expect volum leverag effici initi off-set
invest fx headwind
iqvia cog sg revenu
ep came estim
street revenu came estim upsid quarter
driven equal part oper improv ebitda beat well line
item includ modestli lower tax rate vs model share count
iqvia ep y/i growth
flow oper posit million adjust net
incom work capit headwind capital-expenditure million repres
revenu y/i manag repurchas million worth
share quarter februari iqvia increas share repurchas
author billion bring remain author billion iqvia
end quarter net debt ttm adj ebitda
estestestestestestestestincom statement servic growth servic growth growth constant currenc organ good revenu inc revenu inc gross margin inc expens inc compens stock comp sg total sg y/i ebitda y/i ebitda y/i adj ebit y/i annual bs annual bs debt item expens pre-tax tax earn unconsolid interest/minor net net net y/i basic dilut y/i net barclay iqvia
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
